CRISPR cancer therapy trial halted: what happened with CTX110?

NCT ID NCT04035434

Terminated Disease control Sponsor: CRISPR Therapeutics AG Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 20 times

Summary

This study tested a one-time treatment using CRISPR-edited immune cells from a donor (CTX110) in 93 adults with B-cell cancers like lymphoma or leukemia that had come back or stopped responding to other treatments. The goal was to see if these cells were safe and could shrink tumors. The trial was terminated early, so results are limited, but the approach aimed to control the disease rather than cure it, as patients may need ongoing monitoring or additional therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
CHU de Lille

Lille, 59000, France
Cedars Sinai

Los Angeles, California, 90048, United States
Clinica Universidad de Navarra

Pamplona, Navarre, 31008, Spain
Duke University

Durham, North Carolina, 27710, United States
Emory University Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

Dallas, Texas, 75390, United States
Hospital Clínic de Barcelona

Barcelona, 08036, Spain
Hospital Universitario de Salamanca

Salamanca, 37007, Spain
Hôpital Saint Antoine

Paris, 75012, France
Institut Paoli-Calmettes

Marseille, 13009, France
Markey Cancer Center, University of Kentucky

Lexington, Kentucky, 40536, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
Roswell Park Cancer Insitute

Buffalo, New York, 14203, United States
Royal Prince Alfred Hospital

Sydney, New South Wales, 2050, Australia
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Sir Charles Gairdner Hospital

Nedlands, Western Australia, 6009, Australia
Swedish Cancer Institute

Seattle, Washington, 98104, United States
Texas Transplant Institute

San Antonio, Texas, 78229, United States
UCSF Medical Center

San Francisco, California, 94143, United States
University Hospital Würzburg

Würzburg, 97080, Germany
University of Chicago

Chicago, Illinois, 60637, United States
University of Hamburg

Hamburg, 20148, Germany
University of Kansas

Westwood, Kansas, 66205, United States
University of Maryland

Baltimore, Maryland, 21201, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States
Virginia Commonwealth University Massey Cancer Center

Richmond, Virginia, 23298, United States
Washington University

St Louis, Missouri, 63130, United States
Weill Cornell Medical College / New York Presbyterian Hospital

New York, New York, 10021, United States

Conditions

Explore the condition pages connected to this study.

ADULT B CELL ALL B-CELL LYMPHOMA B-CELL LYMPHOMA B-CELL MALIGNANCY B-CELL MALIGNANCY NON HODGKIN LYMPHOMA